Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Decreases By 22.9%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the recipient of a significant decline in short interest in the month of April. As of April 15th, there was short interest totalling 431,400 shares, a decline of 22.9% from the March 31st total of 559,500 shares. Based on an average trading volume of 312,600 shares, the short-interest ratio is currently 1.4 days.

Analyst Ratings Changes

A number of research analysts have issued reports on MIST shares. Piper Sandler decreased their target price on Milestone Pharmaceuticals from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Tuesday, March 5th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research note on Friday, March 22nd.

Institutional Trading of Milestone Pharmaceuticals

A hedge fund recently raised its stake in Milestone Pharmaceuticals stock. BML Capital Management LLC increased its stake in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 62.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 442,352 shares of the company’s stock after acquiring an additional 169,852 shares during the period. Milestone Pharmaceuticals comprises approximately 0.6% of BML Capital Management LLC’s investment portfolio, making the stock its 23rd largest holding. BML Capital Management LLC owned 1.32% of Milestone Pharmaceuticals worth $739,000 as of its most recent SEC filing. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Stock Down 2.5 %

Shares of Milestone Pharmaceuticals stock traded down $0.04 during trading on Friday, reaching $1.54. The stock had a trading volume of 469,849 shares, compared to its average volume of 138,660. The company has a market capitalization of $81.85 million, a price-to-earnings ratio of -1.11 and a beta of 1.77. The stock has a fifty day moving average price of $1.67 and a two-hundred day moving average price of $2.06. Milestone Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $4.49. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 2.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Sell-side analysts predict that Milestone Pharmaceuticals will post -1.15 EPS for the current fiscal year.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.